Curetis N.V.

https://www.curetis.com

Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques. To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical and Cempra Inc. as well as several international distribution agreements covering many countries across Europe, the Middle East and Asia. *

	Start	2015-11-01 established
	Group	Curetis (Group)
	Predecessor	Curetis AG
	Industry	Unyvero molecular diagnostics platform
	Industry 2	Unyvero P50™ pneumonia cartridge
	Person	Schacht, Oliver (Curetis 201012– CEO before Epigenomics CFO)
	Person 2	Boos, Andreas (Curetis 200812– Managing Director)

	Region	Amsterdam
	Country	Netherlands
	City	n. a. Amsterdam
		Address record changed: 2020-12-02

Basic data	Employees	C: 51 to 100 (2019-04-01)
	Currency	EUR
	Annual sales	1,419,000 (revenue, consolidated (2018) 2018-12-31)
	Profit	-23,745,000 (2018-12-31)
	Cash	7,800,000 (2019-06-30)

		* Document for ï¿½About Sectionï¿½: Curetis N.V.. (4/12/16). "Press Release: Curetis Publishes Full-year 2015 Financial Results and Introduces 2016 Guidance". Amsterdam & Holzgerlingen.

		Record changed: 2020-04-16